文献速递造血干细胞移植与细胞治疗

低剂量白介素-2治疗儿童及年轻成人难治性慢性移植物抗宿主病的真实世界经验

Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease.
PubMed 文献 · Blood Adv · 2023-01-01

本研究回顾性分析了本中心2016年8月至2022年7月接受低剂量白介素-2(LD IL-2)治疗的15例激素难治性慢性移植物抗宿主病(SR-cGVHD)儿童及年轻成人患者,中位年龄10.4岁,中位治疗时长462天。治疗超过4周的13例患者总缓解率为85%(完全缓解5例,部分缓解6例),多数患者显著减少糖皮质激素用量,调节性T细胞优先扩增,未观察到严重不良反应。

要点

  • 15例SR-cGVHD儿童及年轻成人接受LD IL-2,中位年龄10.4岁,中位治疗462天
  • 治疗超过4周的13例患者总缓解率85%(完全缓解5例,部分缓解6例)
  • 调节性T细胞与CD4+常规T细胞比值中位峰值扩增2.8倍,未观察到严重不良反应

核心结论

  • LD IL-2是一种耐受性良好、可减少糖皮质激素用量的药物,在儿童及年轻成人SR-cGVHD中具有高缓解率。

研究设计与样本

  • 本中心回顾性病历审查,纳入2016年8月至2022年7月接受LD IL-2治疗的非研究试验SR-cGVHD儿童及年轻成人共15例。
  • LD IL-2启动时中位年龄10.4岁(范围1.2-23.2岁),距cGVHD诊断中位234天(范围11-542天)。
  • LD IL-2启动时中位受累活动器官数2.5个(范围1-3个),既往接受中位3种治疗(范围1-5种)。
  • LD IL-2中位治疗时长462天(范围8-1489天),多数患者接受1×10⁶ IU/m²每日。

主要发现

  • 13例接受超过4周治疗的患者总缓解率为85%(完全缓解5例,部分缓解6例),缓解见于多种器官。
  • 多数患者显著减少糖皮质激素用量。
  • 调节性T细胞优先扩增,治疗8周时调节性T细胞与CD4+常规T细胞比值中位峰值扩增2.8倍(范围2.0-19.8)。
  • 未观察到严重不良反应。

局限性

  • 本研究为回顾性病历审查,非研究试验。
  • 样本量为15例儿童及年轻成人。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The majority of patients with chronic graft-versus-host disease (cGVHD) are steroid refractory (SR), creating a need for safe and effective therapies. Subcutaneous low-dose interleukin-2 (LD IL-2), which preferentially expands CD4+ regulatory T cells (Tregs), has been evaluated in 5 clinical trials at our center with partial responses (PR) in ∼50% of adults and 82% of children by week 8. We now report additional real-world experience with LD IL-2 in 15 children and young adults. We conducted a retrospective chart review of patients with SR-cGVHD at our center who received LD IL-2 from August 2016 to July 2022 not on a research trial. The median age at start of LD IL-2 was 10.4 years (range, 1.2-23.2 years) at a median of 234 days from cGVHD diagnosis (range, 11-542 days). Patients had a median of 2.5 (range, 1-3) active organs at LD IL-2 start and received a median of 3 (range, 1-5) prior therapies. The median duration of LD IL-2 therapy was 462 days (range, 8-1489 days). Most patients received 1 × 106 IU/m2 per day. There were no serious adverse effects. The overall response rate in 13 patients who received >4 weeks of therapy was 85% (complete response, n = 5; PR, n = 6) with responses in diverse organs. Most patients significantly weaned corticosteroids. Tregs preferentially expanded with a median peak fold increase of 2.8 in the ratio of Tregs to CD4+ conventional T cells (range, 2.0-19.8) by 8 weeks on therapy. LD IL-2 is a well-tolerated, steroid-sparing agent with a high response rate in children and young adults with SR-cGVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wobma H, Kapadia M, Kim HT, et al. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. 2023. PMID: 37603347. doi:10.1182/bloodadvances.2023009729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。